Targeted drugs plus chemo for T-cell acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding targeted drugs to standard chemotherapy works better for adults newly diagnosed with T-ALL. If you have not had any prior treatment for leukemia, this study might be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) and have never received treatment for it.
- You are 18 years or older.
- You are in generally good health (able to carry out daily activities without major issues).
- You do not have any other active cancer or serious heart, liver, kidney, or bleeding problems.
- You are not pregnant, breastfeeding, or HIV-positive.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests adding new immunotherapy drugs and possibly a stem cell transplant to the first treatment for adults with acute lymphoblastic leukemia (ALL). The goal is to see if these approaches help people live longer without the cancer coming back.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.